Sign in Register

Drug class

Calcimimetic, Parathyroid Calcium Recep Sensitivity Enhancer

Calcimimetics, parathyroid calcium receptor sensitivity enhancers, are a therapeutic class of agents that directly lower parathyroid hormone levels by increasing the sensitivity of calcium-sensing receptors on parathyroid cells to activation by extracellular calcium. Read more about Calcimimetic, Parathyroid Calcium Recep Sensitivity Enhancer

19 drugs in this class 15 manufacturers

Related classes & indications

Antihyperglycemic-dipeptidyl peptidase-4 (DPP-4) InhibitorsEndocrine & metabolic · 49 prescription drugs 5 Alpha-Reductase InhibitorsEndocrine & metabolic · 44 prescription drugs Hyperparathyroidism Secondary To Chronic Renal Failure With DialysisTop indication · 35 prescription drugs

Showing 10–18 of 19 drugs

Sort

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER · PARATHYROID CARCINOMA WITH HYPERCALCEMIA ·+2

CAMBER PHARMACE

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER · PARATHYROID CARCINOMA WITH HYPERCALCEMIA ·+2

SUN PHARMA GLOB

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER · PARATHYROID CARCINOMA WITH HYPERCALCEMIA ·+2

DR.REDDY'S LAB

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER · PARATHYROID CARCINOMA WITH HYPERCALCEMIA ·+2

BRYANT RANCH PR

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER · PARATHYROID CARCINOMA WITH HYPERCALCEMIA ·+2

STRIDES PHARMA

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER · PARATHYROID CARCINOMA WITH HYPERCALCEMIA ·+2

ASCEND LABORATO

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER · PARATHYROID CARCINOMA WITH HYPERCALCEMIA ·+2

ACI HEALTHCARE

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER · PARATHYROID CARCINOMA WITH HYPERCALCEMIA ·+2

XLCARE PHARMACE

CINACALCET HCL

CALCIMIMETIC, PARATHYROID CALCIUM RECEP SENSITIVITY ENHANCER · PARATHYROID CARCINOMA WITH HYPERCALCEMIA ·+2

EXELAN PHARMACE

Filter & compare in the drug finder → Opens the drug finder with Calcimimetic, Parathyroid Calcium Recep Sensitivity Enhancer preselected. Add indication or manufacturer filters there.

About Calcimimetic, Parathyroid Calcium Recep Sensitivity Enhancer.

Calcimimetics, parathyroid calcium receptor sensitivity enhancers, are a therapeutic class of agents that directly lower parathyroid hormone levels by increasing the sensitivity of calcium-sensing receptors on parathyroid cells to activation by extracellular calcium.

By allosterically enhancing receptor activation at lower ambient calcium concentrations, these drugs suppress parathyroid hormone secretion and subsequently decrease serum calcium and phosphorus concentrations.

Clinically, medications in this class—such as cinacalcet and etelcalcetide—are primarily used to manage secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as severe hypercalcemia in individuals with primary hyperparathyroidism or parathyroid carcinoma.

fda.gov
Calcimimetics, parathyroid calcium receptor sensitivity enhancers, are a therapeutic class of agents that directly lower parathyroid hormone levels by increasing the sensitivity of calcium-sensing receptors on parathyroid cells to activation by extracellular calcium By allosterically enhancing receptor activation at lower ambient calcium concentrations, these drugs suppress parathyroid hormone secretion and subsequently decrease serum calcium and phosphorus concentrations Clinically, medications...
amgen.com
Calcimimetics, parathyroid calcium receptor sensitivity enhancers, are a therapeutic class of agents that directly lower parathyroid hormone levels by increasing the sensitivity of calcium-sensing receptors on parathyroid cells to activation by extracellular calcium
wikipedia.org
Calcimimetics, parathyroid calcium receptor sensitivity enhancers, are a therapeutic class of agents that directly lower parathyroid hormone levels by increasing the sensitivity of calcium-sensing receptors on parathyroid cells to activation by extracellular calcium Clinically, medications in this class—such as cinacalcet and etelcalcetide—are primarily used to manage secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as severe hypercalcemia in individuals...
nih.gov
By allosterically enhancing receptor activation at lower ambient calcium concentrations, these drugs suppress parathyroid hormone secretion and subsequently decrease serum calcium and phosphorus concentrations
fda.gov
Clinically, medications in this class—such as cinacalcet and etelcalcetide—are primarily used to manage secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as severe hypercalcemia in individuals with primary hyperparathyroidism or parathyroid carcinoma
fda.gov
Clinically, medications in this class—such as cinacalcet and etelcalcetide—are primarily used to manage secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as severe hypercalcemia in individuals with primary hyperparathyroidism or parathyroid carcinoma